Published in
Taylor and Francis Group, Expert Opinion on Drug Discovery, 10(16), p. 1085-1090, 2021
DOI: 10.1080/17460441.2021.1935860
Links
Tools
Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 